RCC

Trevi Therapeutics to Participate in Upcoming Conferences

Retrieved on: 
木曜日, 5月 9, 2024
Corporation, Idiopathic pulmonary fibrosis, University, NIHR, NHS foundation trust, IPF, Respiratory Medicine, Doctor of Philosophy, MB, Chronic cough, University of Manchester, Panel, RCC, FRCP, Therapy, Management

Corporate Presentation: May 14 at 12:00 p.m.

Key Points: 
  • Corporate Presentation: May 14 at 12:00 p.m.
  • ET
    Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust.
  • Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator.
  • Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice.

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
木曜日, 5月 9, 2024
Immunotherapy, FDA, Society, Nivolumab, Research, National Cancer Institute, Bevacizumab, PD-1, ASCO, Journal, Therapy, Liver, Patient, NCI, SITC, RCC, AACR, Kidney cancer, FFA, Growth, HCC, Pharmaceutical industry

BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
  • These data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.
  • Tempest ended the quarter with $32.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023.
  • Based on its current cash and operating plan, Tempest expects to have sufficient resources to fund operations into the second quarter of 2025.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
月曜日, 5月 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

Retrieved on: 
水曜日, 5月 1, 2024
Conference call, News, RCC, Idiopathic pulmonary fibrosis, IPF, Chronic cough, Therapy, Webcast

NEW HAVEN, Conn., May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2024.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2024.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international).
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Retrieved on: 
金曜日, 4月 26, 2024
Cancer, Safety, Regenerative medicine, TS, Metastasis, Trial of the century, Doctor of Philosophy, Development, Disease, CIRM, Autoimmune disease, Kite Pharma, Research and development, Patient, RCC, CD70, AACR, Clinical trial, Kidney cancer, Therapy, SAN, Pharmaceutical industry

It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.

Key Points: 
  • It is a disease in need of innovation as current therapies are based on a few mechanistic targets and complete response rates are low.
  • The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.
  • Additionally, the grant will support translational and clinical analyses to inform a recommended Phase 2 regimen.
  • A more comprehensive data update from the ongoing trial is planned for later in 2024.

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
火曜日, 4月 30, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Education, PFS, Abbreviated New Drug Application, European Patent Office, Experiment, Breast, NET, ASCO, RCC, Associate, Translation, European Medicines Agency, Hearing, PIN, Drug development, European Patent Convention, Metastasis, Conference, Liver disease, ADC, Stada Arzneimittel, Tablet, Baylor College of Medicine, Distinguishing, Therapy, NHT, Calendar, BIRC, Huntsman Cancer Institute, OS, Dean (education), Docetaxel, PKMYT1, Checkmate, Prostate cancer, ITT, EPO, USP1, University, PARP, Immunotherapy, Superior, PLK4, Patent, Royalty payment, Patient, Society, Acquisition, Translational research, Neoplasm, Share repurchase, Annual general meeting, Baylor University

Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.

Key Points: 
  • Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2024, Exelixis earned $39.6 million in royalty revenues.
  • In January, Exelixis announced the appointments of Mary C. Beckerle, Ph.D., and S. Gail Eckhardt, M.D., to the Exelixis Board of Directors, effective January 5, 2024.
  • Exelixis management will discuss the company’s financial results for the first quarter of 2024 and provide a general business update during a conference call beginning at 5:00 p.m.

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Retrieved on: 
火曜日, 4月 16, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Janus, Third Rock Ventures, Cancer, SCCHN, Cell, Neck, Pembrolizumab, Merck & Co., Infection, Immunotherapy, PD-1, AstraZeneca, Patient, Wellington Management Company, Renal cell carcinoma, RCC, Melanoma, Head, Toxicity, Bristol Myers Squibb, Merck, NSCLC, Autoimmunity, NK, Lung cancer, Vaccine

Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.

Key Points: 
  • Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
  • “We are delighted to have the continued support of RA Capital, and excited to add two top biopharmaceutical companies and experts in oncology to our investor syndicate,” said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • We are pleased to have investors with deep and hands-on expertise in the cytokine space recognizing our early clinical data and our differentiated approach.
  • Initial pharmacokinetic and pharmacodynamic data from the ongoing Phase 1a/1b clinical trial support AB248’s proof of mechanism and activity with a highly differentiated clinical profile.

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Retrieved on: 
火曜日, 4月 16, 2024
Safety, Nivolumab, FIH, Immunotherapy, McCormick Place, ICI, ASCO, Therapy, Patient, Society, Renal cell carcinoma, RCC, Melanoma, Annual general meeting, NSCLC, Lung cancer, Pharmaceutical industry

REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who previously progressed on immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The conference will take place at McCormick Place in Chicago, Illinois, and will also be available virtually from May 31 to June 4, 2024.

Key Points: 
  • The conference will take place at McCormick Place in Chicago, Illinois, and will also be available virtually from May 31 to June 4, 2024.
  • Title: Preliminary results from a First-in-Human (FIH), open-label Phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab.
  • These results mark significant progress, laying the groundwork for the next phase in our clinical development process".
  • Additional information about the trial, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05354102).

Brightn Partners with Rockland Community College to Offer Free Mental Wellness Planning App to Students

Retrieved on: 
木曜日, 4月 11, 2024
Achievement Medal, Community college, School, Partnership, Mental health, RCC, Student, Rockland Community College, Anxiety, Organization, Nursing

CEDAR RAPIDS, Iowa, April 11, 2024 /PRNewswire-PRWeb/ -- Brightn, a leading provider of mental wellness solutions, is proud to announce a groundbreaking partnership with Rockland Community College (RCC), making Brightn's innovative mental wellness planning app available to all students at RCC at no cost.

Key Points: 
  • CEDAR RAPIDS, Iowa, April 11, 2024 /PRNewswire-PRWeb/ -- Brightn , a leading provider of mental wellness solutions, is proud to announce a groundbreaking partnership with Rockland Community College (RCC) , making Brightn's innovative mental wellness planning app available to all students at RCC at no cost.
  • As the first school to join forces with Brightn, RCC sets a precedent for fostering mental wellness within the academic community.
  • "We are excited to partner with Rockland Community College to offer our mental wellness planning app to their students," said Jeff Johnston, CEO of Brightn.
  • "Rockland Community College is thrilled to announce its collaboration with Brightn, bringing their advanced mental wellness app to our students.

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Retrieved on: 
火曜日, 4月 9, 2024
HCC, Head, Growth, Immunotherapy, Patient, Tumor microenvironment, Cancer, Renal cell carcinoma, AACR, Bevacizumab, RCC, Neoplasm, Therapy, Nivolumab, ASCO, Tempest, Kidney cancer

These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.

Key Points: 
  • These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022.
  • “Preclinical data presented at AACR further demonstrate that TPST-1120 has the potential to positively transform the tumor microenvironment and expand the activity of anti-tumor immunity in kidney cancer,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • In preclinical models of renal cell carcinoma (RCC), treatment with TPST-1120 reduced tumor growth by 52%-56% as monotherapy.
  • Additional improvement in anti-cancer activity was demonstrated in combination treatment with standard first-line RCC cabozantinib or anti-PD1 therapy, where tumor inhibition was 81% and 74%, respectively.